Lebwohl, M., Sugarman, J., Pariser, D., Bagel, J., Lin, T. and Israel, R. (2020) “Safety and Tolerability of Fixed Combination Halobetasol Propionate 0.01% And Tazarotene 0.045% (HP/TAZ) Lotion in Patients With Moderate-to-Severe Plaque Psoriasis: Results From a 1-Year, Open-Label Study”, SKIN The Journal of Cutaneous Medicine, 4(1), p. S12. Available at: https://www.jofskin.org/index.php/skin/article/view/826 (Accessed: 30June2022).